Simon Senanu: G6PD Deficiency Testing – What the Lab Must Get Right
Simon Senanu, Medical Laboratory Scientist at Perkins Medical Centre, shared a post on LinkedIn:
”G6PD Deficiency Testing – What the Lab Must Get Right
G6PD deficiency is the most common enzymatic disorder of red blood cells worldwide – yet misinterpretation in the lab remains common.
Accurate diagnosis depends on method selection, timing, and clinical context.
Why It Matters
G6PD maintains NADPH production in red cells.
NADPH protects hemoglobin and cell membranes from oxidative damage.
When activity is low:
- Oxidative stress → Hemoglobin denaturation
- Heinz body formation
- Hemolysis
Common triggers:
- Infections
- Oxidant drugs (e.g., sulfa drugs, primaquine)
- Fava beans
Screening Tests (Qualitative)
Fluorescent Spot Test (FST)
G6PD generates NADPH, which fluoresces under UV light.
Reduced fluorescence → deficiency suspected.
- Rapid
- Cost-effective
- Ideal for screening programs
Limitations:
- May miss intermediate deficiency (heterozygous females)
- False normal during acute hemolysis
- Does not quantify activity
Methemoglobin Reduction Test (Sodium Nitrite + Methylene Blue Method)
This is a functional oxidative challenge test performed in a single reaction system.
- Sodium nitrite oxidizes hemoglobin → methemoglobin (brown color).
- Methylene blue acts as an artificial electron carrier.
- G6PD generates NADPH, which reduces methylene blue.
- Reduced methylene blue facilitates conversion of methemoglobin back to hemoglobin.
Interpretation
- Restoration of red color indicates Normal
- Partial restoration(light brown) indicates Partial/intermediate deficiency
- Persistent brown color indicates Deficiency
A functional redox screening test.
Limitations:
- Semi-quantitative, subjective, and affected by hemolysis or incubation conditions.
- Primarily used in low-resource or teaching settings.
Quantitative Enzyme Assay (Diagnostic Standard)
Spectrophotometric Assay
Measures NADPH production rate per gram of hemoglobin.
Provides:
- Exact enzyme activity
- Classification (normal, intermediate, deficient)
- Clinical risk stratification
This is the reference diagnostic method.
Critical Laboratory Pitfalls
- Acute hemolysis
Older deficient RBCs are destroyed first. Reticulocytes have higher activity → False normal results.
Repeat testing 2-3 months post-episode.
- Recent transfusion
Donor RBCs can mask deficiency. Always review history.
- Female heterozygotes
Due to X-linked lyonization, enzyme levels may fall in the intermediate range.
Qualitative tests may miss these cases.
Molecular Testing
Used when:
- Results are inconclusive
- Neonatal diagnosis is required
- Borderline activity with severe hemolysis
- Genotyping is needed
Laboratory Takeaway
- Screening ≠ Quantification
- Timing is critical
- Always assess hemolysis and transfusion status
- Quantitative assay remains the diagnostic reference
Accurate G6PD diagnosis prevents drug-induced hemolysis and improves patient safety.”

Other posts featuring Simon Senanu on Hemostasis Today.
-
Mar 20, 2026, 16:31Jerome Winegarden: ASH Continues to Show Exceptional Leadership by Advocating for Patients With Blood Diseases
-
Mar 20, 2026, 16:28Breanna Beers: A Remarkable Case of ‘Generation Skipping’ Marfan Syndrome
-
Mar 20, 2026, 16:26Results from The HUNT Study on The Role of Plasma miR-145-5p Levels in Cancer-Associated VTE – JTH
-
Mar 20, 2026, 16:23Eva Soler Espejo։ Atherogenic Index of Plasma and Residual Risk in Atrial Fibrillation
-
Mar 20, 2026, 16:22Welcoming Samer Al Hadidi to the Blood Cancers Team – UT Southwestern Simmons Cancer Center
-
Mar 20, 2026, 16:21Maxime Dely: The Lifesaving Power of Plasma Donations
-
Mar 20, 2026, 16:20Yves Bikorimana: Hemolysis – Why It Ruins Laboratory Results
-
Mar 20, 2026, 16:18Khaled Elshazly: Can We Stop Chemotherapy-Induced Thrombocytopenia from Delaying Treatment?
-
Mar 20, 2026, 15:50Rithwic Mani: Platelet-to-Lymphocyte Ratio as A Simple and Cost-Effective Prognostic Biomarker in Stroke